Vontobel Holding Ltd. Invests $70,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vontobel Holding Ltd. bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,600 shares of the company’s stock, valued at approximately $70,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $5,769,000. Capstone Investment Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $161,000. Benjamin F. Edwards & Company Inc. lifted its position in Recursion Pharmaceuticals by 6,439.6% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock worth $1,274,000 after purchasing an additional 167,302 shares during the period. Scientech Research LLC acquired a new stake in Recursion Pharmaceuticals during the second quarter worth $1,052,000. Finally, Ghisallo Capital Management LLC bought a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at $8,250,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RXRX has been the topic of several recent research reports. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Jefferies Financial Group decreased their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC cut their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, KeyCorp lowered their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $9.40.

Insider Transactions at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total value of $76,351.49. Following the transaction, the director now owns 7,089,007 shares in the company, valued at $47,283,676.69. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the transaction, the director now directly owns 7,089,007 shares of the company’s stock, valued at approximately $47,283,676.69. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Gibson sold 30,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total transaction of $213,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at $5,387,039.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 195,682 shares of company stock worth $1,284,153 over the last 90 days. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Stock Down 4.2 %

Shares of NASDAQ:RXRX opened at $6.33 on Thursday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.50 billion, a P/E ratio of -3.94 and a beta of 0.80. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $15.74. The company’s 50-day moving average price is $6.73 and its two-hundred day moving average price is $7.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same period in the prior year, the business earned ($0.38) EPS. The business’s revenue for the quarter was up 30.9% on a year-over-year basis. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.